CytoSorbents to Present at the 13th Annual Needham Healthcare Conference

   CytoSorbents to Present at the 13th Annual Needham Healthcare Conference

PR Newswire

MONMOUTH JUNCTION, N.J., April 3, 2014

MONMOUTH JUNCTION, N.J., April 3, 2014 /PRNewswire/ --CytoSorbents
Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood
purification to treat life threatening conditions in the intensive care unit,
announced that Dr. Phillip Chan, MD, PhD, Chief Executive Officer of
CytoSorbents, will present a corporate overview at the 13^th Annual Needham
Healthcare Conference at the Westin Grand Central Hotel in New York City, New

Dr. Chan will present from 10:00 - 10:40 AM EDT on Tuesday, April 8, 2014.
The executive management team will also be available during the day for
pre-scheduled one-on-one meetings with institutional investors. A live and
archived audio and slide webcast of the presentation will be available at The presentation will be archived for
at least 30 days.

The Company's flagship product, CytoSorb®, is the only specifically approved
extracorporeal cytokine filter in the European Union. It is clinically proven
to reduce excessive blood levels of cytokines, often called "cytokine storm",
which can drive dangerous and deadly widespread inflammation in critically-ill
patients. This uncontrolled inflammation can rapidly lead to the damage and
failure of vital organs, the cause of nearly half of all deaths in the
intensive care unit (ICU). The goal of CytoSorb® therapy is to prevent or
treat organ failure by reducing severe inflammation in a diverse set of life
threatening conditions such as sepsis, lung injury, trauma, burn injury, and
pancreatitis, as well as during high risk cardiac surgery. CytoSorb® is
commercially available in multiple European and Asian countries.

Needham's Healthcare Conference focuses on connecting leading emerging life
science companies and institutional investors. This year, senior management
teams from approximately 120 companies in the biotechnology, specialty
pharmaceutical, medical technology and diagnostic sectors have been invited
and scheduled to present. 

About CytoSorbents Corporation

CytoSorbents is a critical care focused immunotherapy company using blood
purification to modulate inflammation -- with the goal of preventing or
treating multiple organ failure in life-threatening illnesses. Organ failure
is the cause of nearly half of all deaths in the intensive care unit, with
little to improve clinical outcome. CytoSorb®, the Company's flagship product,
is approved in the European Union as a safe and effective extracorporeal
cytokine filter, designed to reduce the "cytokine storm" that could otherwise
cause massive inflammation, organ failure and death in common critical
illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis.
These are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorbents' purification technologies are based
on biocompatible, highly porous polymer beads that can actively remove toxic
substances from blood and other bodily fluids by pore capture and surface
adsorption. CytoSorbents has numerous products under development based upon
this unique blood purification technology, protected by 32 issued US patents
and multiple applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for download on the
Company's website:

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein. Risk factors are detailed
in the Company's Form 10-K filed with the SEC on March 31, 2014, which is
available at

Please Click to Follow us on Facebook and Twitter

SOURCE CytoSorbents Corporation

Contact: Company Contact: CytoSorbents Corporation, Dr. Phillip Chan, MD, PhD,
Chief Executive Officer, (732) 329-8885 ext. *823,;
Investor Contact: CytoSorbents Corporation, Amy Vogel, (732) 329-8885 ext.
Press spacebar to pause and continue. Press esc to stop.